Literature DB >> 15528450

Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters.

Laurent Bardin1, Marie-Bernadette Assié, Martine Pélissou, Isabelle Royer-Urios, Adrian Newman-Tancredi, Jean-Paul Ribet, François Sautel, Wouter Koek, Francis C Colpaert.   

Abstract

The aim of the present study was to establish the relationship between the plasma and brain concentration-time profiles of F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt] after acute administration and both its hyper- and hypoanalgesic effects in rats. The maximal plasma concentration (C(max)) of F 13640 after i.p. administration of 0.63 mg/kg was obtained at 15 min and decreased to half its maximal value after about 1 h. The amount of F 13640 collected by means of in vivo microdialysis in hippocampal dialysates could be measured reliably after 0.63 and 2.5 mg/kg, reached its maximum at about 1 h, and fell to half of its maximal value at about 3 h. 5-Hydroxytryptamine 1A (5-HT(1A)) receptor occupancy was estimated by ex vivo binding in rat brain sections. F 13640 inhibited [(3)H]8-hydroxy-2-[di-n-propylamino] tetralin binding ex vivo in rat hippocampus, entorhinal cortex, and frontal cortex (ED(50), 0.34 mg/kg i.p.). Maximal inhibition was reached at approximately 30 min after 0.63 mg/kg F 13640 and fell to half of its value after about 4 to 8 h. After injection (15 min) in the paw pressure test, F 13640 (0.63 mg/kg i.p.) induced an initial hyperalgesia that was followed 4 h later by a paradoxical analgesia that lasted until 8 h. In contrast, in the formalin test, F 13640 inhibited pain behaviors until 4 h after drug administration. F 13640 also produced elements of the 5-HT syndrome that lasted up to 4 h after administration. These results demonstrate that F 13640 induces hyperalgesia and/or analgesia with a time course that parallels the occupancy of 5-HT(1A) receptors and the presence of the compound in blood and brain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15528450     DOI: 10.1124/jpet.104.077669

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.

Authors:  Laia Lladó-Pelfort; Marie-Bernadette Assié; Adrian Newman-Tancredi; Francesc Artigas; Pau Celada
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

2.  [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.

Authors:  Peter Heusler; Christiane Palmier; Stéphanie Tardif; Sophie Bernois; Francis C Colpaert; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-27       Impact factor: 3.000

3.  The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway.

Authors:  Zifeng Xu; Bin Yang; Jianhai Zhang; Jijian Zheng
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 4.  For the love of paradox: from neurobiology to pharmacology.

Authors:  Richard A Bond; Heather Giles
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 5.  The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword.

Authors:  Jun Chen; William R Lariviere
Journal:  Prog Neurobiol       Date:  2010-06-15       Impact factor: 11.685

6.  5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception.

Authors:  J-C Martel; M-B Assié; L Bardin; R Depoortère; D Cussac; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

7.  The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets.

Authors:  Ria Fisher; Atsuko Hikima; Rebecca Morris; Michael J Jackson; Sarah Rose; Mark A Varney; Ronan Depoortere; Adrian Newman-Tancredi
Journal:  Neuropharmacology       Date:  2020-02-10       Impact factor: 5.250

8.  Effect of buspirone on thermal sensory and pain thresholds in human volunteers.

Authors:  Goran Pavlaković; Julija Tigges; Thomas A Crozier
Journal:  BMC Clin Pharmacol       Date:  2009-05-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.